Albert J. ten Tije

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.5K citations · Full text

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +9

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 562 citations

Surgical Oncology, Chemotherapy Versus Chemoradiotherapy, Gastrointestinal Oncology +8

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May et al. · The Lancet · 2015 · 511 citations

Oncology, Gastrointestinal Oncology, Maintenance Treatment +10

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 403 citations · Full text

Medicine, Prospective Safety Analysis, Cancer Management +9